MHRA kicks off new ac­cel­er­at­ed drug ap­proval path­way with ‘in­no­va­tion pass­ports’

As the UK no longer par­tic­i­pates in the Eu­ro­pean Med­i­cines Agency, the coun­try’s drug reg­u­la­tor is get­ting cre­ative in try­ing to at­tract top bio­phar­ma com­pa­nies to sub­mit ap­pli­ca­tions to the EU and UK sep­a­rate­ly.

As part of this cre­ative push, the UK’s Med­i­cines and Health­care prod­ucts Reg­u­la­to­ry Agency (MHRA), the UK’s stand­alone med­i­cines and med­ical de­vices reg­u­la­tor, last week un­veiled a new ac­cel­er­at­ed drug ap­proval path­way, known as the In­no­v­a­tive Li­cens­ing and Ac­cess Path­way (ILAP).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER